Featuring news, events and industry trends
Goldilocks Therapeutics, Inc. Awarded a $300K Phase I Small Business Innovation Research (SBIR) Grant

The grant received from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) is entitled: “Efficacy and pharmacokinetic assessment of renal-targeted therapy in a pig model of cisplatin induced acute kidney injury.” This work is designed to provide the first large-animal proof-of-concept showing efficacy using the Company’s mesoscale nanoparticle (MNP) platform. It is estimated that over 100,000 cancer patients in the U.S. receive cisplatin annually; about 30% of these individuals develop AKI, which interferes with their ability to receive optimal chemotherapy.
Regeneron Pharmaceuticals, Inc. and Sanofi Announce Results from a Second Phase 3 Trial Assessing the Investigational Use of Dupixent® (dupilumab) Phase 3 Eosinophilic Esophagitis Trial to Demonstrate Significant Disease Improvements, Underscoring Role of Type 2 Inflammation in This Complex Disease

Tarrytown-headquartered, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi announced results from a second Phase 3 trial assessing the investigational use of Dupixent® (dupilumab) in patients 12 years and older with eosinophilic esophagitis (EoE). The trial met its co-primary endpoints in patients taking Dupixent 300 mg weekly, showing significant improvements in clinical (Dysphagia Symptom Questionnaire) and histologic disease measures compared to placebo. In September 2020, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to Dupixent for the treatment of patients 12 years and older with EoE.

Dupixent 300 mg weekly significantly improved the ability to swallow and reduced eosinophils in the esophagus compared to placebo, reinforcing positive results from first Phase 3 trial. Eosinophilic esophagitis is a progressive disease that damages the esophagus and impairs the ability to swallow; 90% of trial participants had at least one coexisting type 2 inflammatory condition such as asthma or atopic dermatitis.
Sapience Therapeutics Announces Multiple Poster Presentations on ST101 at 28th Prostate Cancer Foundation Annual Scientific Retreat and 18th International Congress of the Society for Melanoma Research

Harrison-based, Sapience Therapeutics, Inc., a biotechnology company focused on the discovery and development of peptide therapeutics to address difficult-to-treat cancers, announced it will present multiple posters on its lead program, ST101, at the 28th Prostate Cancer Foundation (PCF) Annual Scientific Retreat and the 18th International Congress of the Society for Melanoma Research.
Life Sciences Real Estate Development Symposium

The Fourth Annual NYC Builds Bio+ Real Estate Development Symposium will focus on the Greater New York Metropolitan area (which also encompasses eastern New Jersey and southern Connecticut), and how it has emerged as the largest and one of the fastest growing life sciences economies in the country.

Join the Fourth Annual Life Science Real Estate Development Symposium to hear how private and public investments are driving exponential growth for the life science industry, what new initiatives are furthering innovation in the space and what this means for the Greater NY Metropolitan Area.

Date: November 4
Time: 8:00 AM – 3:00 PM
A Glimpse Into the Mind of the Life Science Investor

You have an idea, started some experiments, but it is time to move your idea forward and you need seed capital to take those next steps. Where do you go and how do you do it? What operational steps need to be taken?

In this program you will hear from individuals whose companies have successfully raised startup capital and investors who provide those funds. Additionally, will discuss the early-stage process that can help you get started on better footing so your journey can be smoother. You will also hear hand selected, pre-series A JLABS companies pitch to investors as they look for that next funding round.

Date: November 4, 2021 
Time: 11:30 AM – 2:00 PM 
Crossing the Valley of Death: Lab to IPO and Lab to Acquisition

On November 30th hear from Josep Bassaganya-Riera, Chairman and CEO Landos BioPharma, and Matthew Meyer, former Chief Business officer CAREDx and now Chief Buisness Advisor Wilson Sonsini, as they share their journey crossing the chasm to lead ventures from academia to the public market.

Immediately following the Q&A portion of the panel, you'll have an opportunity to meet and talk with the speakers at virtual tables.

Date: November 30, 2021
Time: 1:00 PM – 2:30 PM

Have good news to share from
Westchester’s biosciences ecosystem?

Please let us know.

If you would like to continue receiving this weekly newsletter,
please sign up below. If you would like to contact us directly, click the Contact Us link.